Methylphenidate Medical Valley

Methylphenidate, the active ingredient in Methylphenidate Medical Valley, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder and narcolepsy in children, adolescents and adults.

GNH USA supplies Methylphenidate Medical Valley as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate is a central nervous system stimulant indicated for the following conditions:

- Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity in children, adolescents and adults. - Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.

Methylphenidate may cause a range of adverse reactions. The most frequently reported events are generally mild to moderate in severity.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Nausea: feeling of sickness, sometimes with vomiting.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychosis or severe agitation: hallucinations, delusional thinking. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing methylphenidate, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate blood pressure and heart rate, especially in patients with pre‑existing heart disease. - Psychiatric history: monitor for emergence of psychotic symptoms or severe mood changes. - Growth monitoring: track height and weight in pediatric patients due to appetite suppression. - Substance‑use risk: assess for potential misuse or dependence. - Drug‑interaction review: check concomitant medications that may affect catecholamine levels. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Methylphenidate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antipsychotics with strong dopamine blockade: reduced efficacy of methylphenidate.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): may enhance serotonergic activity. - Antihypertensive agents: possible attenuation of blood‑pressure‑lowering effect. - Antacids or proton‑pump inhibitors: may alter absorption of oral formulations.